title: Mechanisms of organ selective tumour growth by bloodborne cancer cells.
abstract: The sites of tumour development for 6 rat tumours injected into syngeneic rats via different vascular routes was determined. Xenografts of human tumours were also injected intra-arterially (i.a.) into immunosuppressed rats. Following intravenous (i.v.) and intraportal (i.ptl.) injection of cells tumour colonies localized in lung and liver respectively due to tumour cell arrest. Arterially injected radiolabelled cells disseminated and arrested in a similar distribution to cardiac output and did not 'home' to any organs. Following arterial injection of unlabelled tumour cells colonies grew in many organs. While the pattern of growth for a particular tumour varied with the cell dose, the 'arterial patterns' for all of the tumours studied followed a similar pattern. Some organs (eg adrenals, ovaries and periodontal ligament) were consistently preferred, others (eg skin and skeletal muscle) only supported tumour growth following the delivery of large numbers of cells, while in some tissues (eg spleen and intestines) tumour never grew. Viable tumour cells could be demonstrated by bioassay in many organs for up to 24h after i.a. injection. However tumour growth only occurred in certain organs and the pattern of this growth was not related to the number of tumour cells arrested or their rate of autolysis. This site preference could be expressed quantitatively as the probability of an arrested cell developing into a tumour and was considered a 'soil effect'. Site preference was not directly related to organ vascularity. Organ colonisation was promoted by steroid treatment but the mechanism was unclear and was not secondary to T-cell immunosuppression or prostaglandin synthesis suppression. The adrenal glands were preferred sites of tumour growth but pharmacological manipulation of adrenal function did not alter tumour growth to this organ. Sites of injury and healing were preferred sites of tumour colonisation and this could not be accounted for by increased delivery of tumour cells to these regions. The possibility that the macrophage component of the inflammatory response promoted tumour growth was suggested from studies in which the interval between trauma and inoculation of tumour cells was varied as well as by promotion of intraperitoneal (i.p.) tumour growth by a macrophage infiltrate.
authors.affiliation: University Surgical Unit, Southampton General Hospital, UK.
authors.forename: P
authors.initials: P
authors.lastname: Murphy
authors.forename: P
authors.initials: P
authors.lastname: Alexander
authors.forename: P V
authors.initials: PV
authors.lastname: Senior
authors.forename: J
authors.initials: J
authors.lastname: Fleming
authors.forename: N
authors.initials: N
authors.lastname: Kirkham
authors.forename: I
authors.initials: I
authors.lastname: Taylor
mesh_terms: D000818:Animals; D002273:Carcinogens / Q000494:pharmacology; D002302:Cardiac Output; D003524:Cyclosporins / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D005480:Flurbiprofen / Q000494:pharmacology; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000556:secondary*; D008175:Lung Neoplasms / Q000556:secondary*; D008297:Male; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental; D009360:Neoplastic Cells, Circulating; D011169:Portal Vein; D051381:Rats; D011919:Rats, Inbred Strains; D012039:Regional Blood Flow; D013729:Terpenes / Q000494:pharmacology
chemical_list: D002273:Carcinogens; D003524:Cyclosporins; D013729:Terpenes; C009042:pristane; D005480:Flurbiprofen; D003907:Dexamethasone